Global Mono Hepatitis A Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Mono Hepatitis A Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Mono Hepatitis A Vaccine market finds that the global Mono Hepatitis A Vaccine market reached a value of USD 813.71 million in 2022. It’s expected that the market will achieve USD 1203.0 million by 2028, exhibiting a CAGR of 6.73% during the forecast period.

Strict supervision system

A vaccine is a biological product. Biological products are complex in the production, circulation and use process. In addition, all countries have strict regulatory systems for vaccine products to ensure product safety. Due to the complexity of its supervisory agencies and regulations, as well as the different approval systems of various countries, the industry has a high barrier to entry.

The United States has a relatively complete series of vaccine management laws such as the Vaccine Supervision and Management Act and the Public Health Service Act, and has established a safety supervision organization system, including the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and health resources and service management Bureau (HRSA), Food and Drug Administration (FDA), and other 4 federal government agencies.

Decline in the global birth rate

The decline in fertility is becoming one of the most fundamental social changes in human history. Although the decline in the birth rate is more reflected in developed countries such as Germany and Japan, it actually includes developing countries such as China, Vietnam, Thailand, Iran, Chile, and Uruguay, whose birth rates have fallen below the replacement level (that is, the average Women have 2.1 children in their lifetime), and as more and more countries make economic progress, the fertility rate in more countries will decrease.

As the number of new-born populations in more countries stabilizes or even decreases, the hepatitis A vaccine market will be relatively saturated, and the growth rate of usage in many countries may decline. This will greatly increase the risk of market entry.

Region Overview:

Geographically, Asia Paciffic held the largest market share – 37.14% in 2022.

Company Overview:

MSD is one of the major players operating in the Mono Hepatitis A Vaccine market, holding a share of 37.36% in 2023.

MSD

They are a research-based healthcare company. Their research and development work is currently focused on the following medical areas: cardiovascular health, diabetes, and endocrinology (including gynecology), neurology and ophthalmology, oncology, infectious diseases, respiratory diseases, and immunology.

Sanofi

Sanofi is a healthcare company engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new G enzyme. Its products includes prescriptions and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines and other medical products.

Segmentation Overview:

As for product types, the Inactivated Vaccine segment held the largest market share in 2022.

Inactivated Vaccine

Inactivated vaccines are vaccines composed of virus particles, bacteria or other pathogens. These viruses, bacteria or other pathogens have grown in culture and then lose their ability to cause disease.

Live Attenuated Vaccine

Live attenuated vaccine (LAV) Live attenuated vaccine (LAV) is a vaccine prepared from live microorganisms (viruses, currently available bacteria) that have been weakened under laboratory conditions. The LAV vaccine will replicate and produce an immune response in the vaccinated individual, but usually does not cause mild or no disease.

Application Overview:

The market's largest segment by application is the segment Government Institution, with a market share of 54.1% in 2022.

Key Companies in the global Mono Hepatitis A Vaccine market covered in Chapter 3:

Sinovac
Zhejiang Pukang
GSK
Changchun Institute of Biological
Sanofi
MSD
IMBCA

In Chapter 4 and Chapter 14.2, on the basis of types, the Mono Hepatitis A Vaccine market from 2018 to 2029 is primarily split into:

Inactivated Vaccine
Live Attenuated Vaccine

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Mono Hepatitis A Vaccine market from 2018 to 2029 covers:

Government Institution
Private Sector
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)